Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Newcomer, John W.; Ng-Mak, Daisy; Rajagopalan, Krithika; Loebel, Antony

doi:10.1186/s12913-018-3020-2

Table 1 Pre-index patient characteristics

From: Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Variable	Combined population				Medicaid population				Commercial population
	Lurasidone		Quetiapine		Lurasidone		Quetiapine		Lurasidone		Quetiapine
	n = 238		n = 435		n = 122		n = 215		n = 116		n = 220
Demographics
Age, (Mean, SD)	37.1	13.4	37.6	14.2	39.1	12.8	38.2	12.9	34.9	13.8	36.9	15.3
Female (N, %)	145	61	225*	52	82	67	129	60	63	54	96	44
Comorbidities, (N, %)
Psychiatric
Alcohol/Substance Abuse	53	22	159*	37	41	34	84	39	12	10	75*	34
Anxiety	67	28	170*	39	39	32	84	39	28	24	86*	39
Bipolar Disorder	108	45	231	53	57	47	106	49	51	44	125*	57
Depression	99	42	225*	52	51	42	117*	54	48	41	108	49
Personality Disorders	25	11	45	10	18	15	28	13	7	6	17	8
Cardiometabolic
Diabetes	41	17	61	14	25	21	39	18	16	14	22	10
Hyperlipidemia	48	20	93	21	30	25	52	24	18	16	41	19
Hypertension	69	29	144	33	49	40	88	41	20	17	56	25
Medications, (N, %)
Psychiatric
Antidepressants	177	74	313	72	98	80	169	79	79	68	144	66
Anxiety	65	27	172*	40	27	22	78*	36	38	33	94	43
Hypnotics	80	34	142	33	53	43	84	39	27	23	58	26
Mood stabilizers	130	55	269	62	67	55	130	61	63	54	139	6
Stimulants	21	9	22	5	1	1	3	1	20	17	19*	9
Typical antipsychotics	23	10	63	15	12	10	29	14	11	10	34	15
Other
Antidiabetics	38	16	50	12	22	18	30	14	16	14	20	9
Antihypertensives	62	26	124	29	43	35.	72	33	19	16	52	24
Antilipidemic	55	23	76	18	36	29	40*	19	19	16	36	16
Switch from atypical antipsychotic
Aripiprazole	58	24	90	21	26	21	41	19	32	28	49	22
Asenapine	24	10	10*	2	12	10	4*	2	12	10	6*	3
Clozapine	4	2	6	1	2	2	3	1	2	2	3	1
Iloperidone	10	4	13	3	5	4	5	2	5	4	8	4
Paliperidone	43	18	74	17	18	15	30	14	25	22	44	20
Olanzapine	28	12	18*	4	17	14	11*	5	11	10	7*	3
Risperidone	56	24	159*	37	27	22	81*	38	29	25	78	35
Ziprasidone	38	16	89	20	23	19	53	25	15	13	36	16
Inpatient admissions, (N, %)
All-cause	98	41	274*	63	44	36	114*	53	54	47	160*	73
Mental health-related	98	41	272*	63	44	36	113*	53	54	47	159*	72
Schizophrenia-related	80	34	214*	4*	34	28	95*	44	46	40	119*	54
Total cost, (Mean, SD)^a					13,883	16,721	15,008	14,086	15,379	17,352	23,061*	30,804

^aExpenditures for the combined Medicaid/Commercial population are not reported due to different payment structures
*p < 0.05; Statistically significantly different from lurasidone cohort

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Health Services Research

Contact us